News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2025

23 October, 2025 Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
15 October, 2025 Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region News Corporate Information Other Corporate Information English IR Optional
10 October, 2025 Egetis’ Nomination Committee for the 2026 Annual General Meeting News Corporate Information Nomination Committee English IR Optional
2 October, 2025 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
2 October, 2025 Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer
21 August, 2025 Interim report Q2 2025 News English Regulatory MAR VPML Report Interim Q2 IR Optional
19 August, 2025 Invitation to Presentation of Egetis’ Second Quarter 2025 Report on August 21, 2025 News Corporate Information Other Corporate Information English IR Optional
18 August, 2025 Egetis reports progress towards US NDA submission for tiratricol News Corporate Information Other Corporate Information English IR Optional
17 July, 2025 CFO of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
15 July, 2025 Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
16 June, 2025 Egetis announces exclusive distribution agreement with Er-Kim for Emcitate® in Türkiye News Corporate Information Other Corporate Information English IR Optional
10 June, 2025 CEO and members of Egetis' Leadership Team acquire shares in Egetis News Corporate Information Other Corporate Information English IR Optional
6 May, 2025 Bulletin from Egetis Therapeutics’ Annual General Meeting 2025 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
5 May, 2025 Egetis Confirms Launch of Emcitate® in Germany News Corporate Information Other Corporate Information English IR Optional
30 April, 2025 Interim report Q1 2025 News English Regulatory MAR Report Interim Q1 IR Optional
25 April, 2025 Invitation to Presentation of Egetis’ First Quarter 2025 Report on April 30, 2025 News Corporate Information Other Corporate Information English IR Optional
25 April, 2025 Article mapping variants in thyroid hormone transporter MCT8 to disease severity published in Nature Communications News Corporate Information Other Corporate Information English IR Optional
11 April, 2025 Egetis Therapeutics’ Annual Report 2024 published News English Regulatory VPML Report Annual IR Optional
3 April, 2025 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
26 February, 2025 Year-End Report January-December 2024 News English Regulatory MAR Report Interim Yearend IR Optional
25 February, 2025 Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025 News Corporate Information Other Corporate Information English IR Optional
21 February, 2025 Invitation to Presentation of Egetis’ Fourth Quarter and Year-End 2024 Report on February 26, 2025 News Corporate Information Other Corporate Information English IR Optional
20 February, 2025 Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day News Corporate Information Other Corporate Information English IR Optional
13 February, 2025 European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

2024

30 December, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
Next

Calendar and upcoming reports

November 11-13, 2025
Stifel Annual Healthcare Conference (New York)

November 17, 2025
LifeSci Capital & Sofinnova, Growth & Innovation Summit (London)

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]